IN192749B - - Google Patents

Info

Publication number
IN192749B
IN192749B IN1155DE2002A IN192749B IN 192749 B IN192749 B IN 192749B IN 1155DE2002 A IN1155DE2002 A IN 1155DE2002A IN 192749 B IN192749 B IN 192749B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Sumit Madan
Anupam Trehan
Vinod Kumar Arora
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN1155DE2002 priority Critical patent/IN192749B/en
Priority to US10/534,909 priority patent/US20060141023A1/en
Priority to AU2003276549A priority patent/AU2003276549A1/en
Priority to CNA2003801070711A priority patent/CN1728996A/zh
Priority to PCT/IB2003/005140 priority patent/WO2004045608A1/en
Publication of IN192749B publication Critical patent/IN192749B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1155DE2002 2002-11-15 2002-11-15 IN192749B (me)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IN1155DE2002 IN192749B (me) 2002-11-15 2002-11-15
US10/534,909 US20060141023A1 (en) 2002-11-15 2003-11-13 Pharmaceutical compositions containing abiguanide-glitazone combination
AU2003276549A AU2003276549A1 (en) 2002-11-15 2003-11-13 Pharmaceutical compositions containing a biguanide-glitazone combination
CNA2003801070711A CN1728996A (zh) 2002-11-15 2003-11-13 含双胍-格列酮组合的药物组合物
PCT/IB2003/005140 WO2004045608A1 (en) 2002-11-15 2003-11-13 Pharmaceutical compositions containing a biguanide-glitazone combination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1155DE2002 IN192749B (me) 2002-11-15 2002-11-15

Publications (1)

Publication Number Publication Date
IN192749B true IN192749B (me) 2004-05-15

Family

ID=32321379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1155DE2002 IN192749B (me) 2002-11-15 2002-11-15

Country Status (5)

Country Link
US (1) US20060141023A1 (me)
CN (1) CN1728996A (me)
AU (1) AU2003276549A1 (me)
IN (1) IN192749B (me)
WO (1) WO2004045608A1 (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2004208606B2 (en) 2003-01-29 2009-09-24 Takeda Pharmaceutical Company Limited Process for producing coated preparation
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
PE20080249A1 (es) * 2006-04-27 2008-04-23 Takeda Pharmaceutical Composicion farmaceutica que contiene pioglitazona
ES2354397T3 (es) 2007-02-01 2011-03-14 Takeda Pharmaceutical Company Limited Preparación sólida que comprende alogliptina y pioglitazona.
JP2010521492A (ja) * 2007-03-15 2010-06-24 ネクティド,インク. 徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼiv阻害剤組成物を含む抗糖尿病合剤
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US20120115799A1 (en) 2010-05-11 2012-05-10 Wenhua Wang Pharmaceutical formulations
ES2609791T3 (es) * 2010-07-06 2017-04-24 Janssen Pharmaceutica, N.V. Fórmula para tratamientos de co-terapia de diabetes
US20120093878A1 (en) * 2010-07-30 2012-04-19 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a thiazolidinedione
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
EP2611434A1 (en) * 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
EA028946B1 (ru) 2011-04-13 2018-01-31 Янссен Фармацевтика Нв Способ получения соединений для применения в качестве ингибиторов sglt2
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
EP2638898A1 (en) * 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin and Pioglitazone Formulation with Different Release Profiles
JPWO2014171542A1 (ja) * 2013-04-19 2017-02-23 武田薬品工業株式会社 放出制御製剤
CN103432128B (zh) * 2013-08-26 2015-11-18 中国人民解放军第150中心医院 一种盐酸吡格列酮缓释微丸制剂含药层的组配方法
CN103432129B (zh) * 2013-08-26 2016-01-27 中国人民解放军第150中心医院 一种盐酸吡格列酮缓释微丸制剂的组配方法
CN103432131A (zh) * 2013-09-11 2013-12-11 中国药科大学 一种含有盐酸吡格列酮和盐酸二甲双胍的复方制剂及其制备方法
CN104473894A (zh) * 2014-12-18 2015-04-01 浙江华海药业股份有限公司 一种盐酸吡格列酮载药包衣制剂及其制备方法
CN105749233A (zh) * 2016-04-11 2016-07-13 温玉平 一种治疗糖尿病的中药组方
CN109330995B (zh) * 2018-12-05 2021-05-18 河北医科大学 一种包载短效降糖药的微丸及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
EP1278513B1 (en) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC A core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes

Also Published As

Publication number Publication date
US20060141023A1 (en) 2006-06-29
AU2003276549A8 (en) 2004-06-15
CN1728996A (zh) 2006-02-01
WO2004045608A9 (en) 2004-08-26
WO2004045608A1 (en) 2004-06-03
AU2003276549A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
BE2019C547I2 (me)
BE2019C510I2 (me)
BE2018C021I2 (me)
BE2017C049I2 (me)
BE2017C005I2 (me)
BE2016C069I2 (me)
BE2016C040I2 (me)
BE2016C013I2 (me)
BE2018C018I2 (me)
BE2016C002I2 (me)
BE2015C078I2 (me)
BE2015C017I2 (me)
BE2014C053I2 (me)
BE2014C051I2 (me)
BE2014C030I2 (me)
BE2014C016I2 (me)
BE2013C039I2 (me)
BE2013C025I2 (me)
JP2003108448A5 (me)
IN192749B (me)
BRPI0302144B1 (me)
BRPI0215435A2 (me)
BE2013C046I2 (me)
JP2003227305A5 (me)
JP2003207131A5 (me)